---
theme: academic
layout: cover
class: text-white
coverAuthor: beau hilton 
coverAuthorUrl: https://www.beauhilton.com
coverDate: "2022-10-28"
themeConfig:
  paginationX: r
  paginationY: t
  paginationPagesDisabled: [1]
title: Pheochromocytoma
info: |
  # Pheochromocytoma
  Case Conference 2022-10-28, [Beau Hilton](https://www.beauhilton.com)

---

# Pheochromocytoma

---


# Case presentation

50M with T1DM, chronic inflammatory demyelinating polyneuritis (monthly IVIG), CKD4, pheochromocytoma 2016 s/p resection, presenting for a second opinion for recently discovered metastatic disease.

<v-clicks>

- 2014-xx-xx  
~50lb weight loss, recurrent diaphoresis and feeling of being hot, extreme fatigue                     
- 2014-06-xx  
presented to OSH                                                                                        
- 2014-06-15  
10.2x9.0x6.8 cm mass on CTAP, taken to surgery.                                                        
 L adrenalectomy, 
 L partial nephrectomy, splenectomy. Clean margins. 7 LN w/o cancer.                    
 Path: mostly necrotic tissue, low Ki-67 (specifics not available).                                      
</v-clicks>

<Footnotes separator>
  <Footnote :number=U+FE61>Details modified, altered, and otherwise fudged for HIPAA compliance and decency.</Footnote>
</Footnotes>

---

# Case presentation

<v-clicks>

- 2021-08-xx  
plasma normetanephrine elevated


- 2021-09-xx  
PET dotatate: 1.8cm nodule in surgical bed, multiple b/l pulm nodules, LN: [paraaortic RP, mediastinal].

</v-clicks>

<v-clicks>

Told to get his affairs in order, consult to VUMC entered.

</v-clicks>

---

# Case presentation

<br>

## Labs

<v-clicks>

- Cr 2.75 (b/l)
- plasma normetanephrine 990
- plasma metanephrine <10
- otherwise bland

</v-clicks>

<br><br>

## Exam


<v-clicks>

- SBP 140s, at baseline
- nothing else of note

</v-clicks>

---

# Questions


<v-clicks>

- How common is pheochromocytoma/paraganglioma?
  - sites of disease?
  - symptoms?
- Is there a link between autoimmunity and pheo/para?
  - Answer: not a robust one.
- After initial management, what should surveillance look like?
  - labs?
  - imaging?
- How should we think about prognosis?
- When should we treat?
- What treatment modalities are available?
  - Any notable differences wrt other NETs?

</v-clicks>
---

# Terminology


## Pheochromocytoma
 
<v-clicks>

Neuroendocrine tumors 

arising from *chromaffin* cells 
of the *adrenal medulla*

(usually, "pheochromocytoma" 
refers specifically to adrenal tumors).

</v-clicks>

## Paraganglioma

<v-clicks>

Same idea, paraganglia NET, but not adrenal (chromaffin staining usually less robust).

</v-clicks>

## PPGL

<v-clicks>

Catch-all term ("pheochromocytoma and paraganglioma")

Different papers use different acronyms for the same thing.

</v-clicks>

---

# Terminology

## Malignant PPGL

Determined by:

<v-clicks>

- ~~imaging~~
- ~~pathology~~
- ~~mutations~~

</v-clicks>

<v-clicks>

"Malignancy can only be determined from the presence of metastatic lesions at sites where chromaffin cells are normally absent."<sup>1</sup>

Proven by bx, 
functional imaging and 
catecholamines can also be helpful.

</v-clicks>

---

# Terminology

## Metastatic, Recurrent, Synchronous

<v-clicks>

Metastatic: wrong place (bone ~60%, distant LN ~40%, lung ~30%, liver ~25%)

Synchronous: multiple right places (sympathetic trunk, H&N)

Recurrent: right place, again

</v-clicks>

<Footnotes separator>
  <Footnote :number=1>Fassnacht 2020</Footnote>
</Footnotes>

---
layout: figure-side
figureFootnoteNumber: 1
figureUrl: ./alsubhi2.png
---


# Epidemiology

<v-clicks>

- Detected incidence for PPGL: 0.6/100k, rising with time
- ~0.5% of all pts with HTN
- ~4% in adrenal incidentaloma
- \>35% of cases are associated w germline mutations
- \~2/3-3/4 p/w with hormone-related sx, \~2/3-3/4 p/w with tumor-related sx

</v-clicks>


<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1210%2Fjendso%2Fbvac105" rel="noreferrer" target="_blank">Al Subhi 2022</a></Footnote>
</Footnotes>

---

# Surveillance

Type and frequency depends on low- vs high-risk status.

## High-risk features

<v-clicks>

- tumor size >=5cm
- any paragangliomata (extra-adrenal)
- SDHx mutation
- plasma methoxytyramine >=3x ULN

</v-clicks>

## If low-risk

<v-clicks>

- metanephrines 2-6wk s/p surgery, then dealer's choice (usu yearly)
- image if metanephrines get out of whack

</v-clicks>

## If high-risk

<v-clicks>

- metanephrines and imaging, at least yearly
- dotatate vs FDG

</v-clicks>

---

# Prognosis

<v-clicks>

## If malignant<sup>1</sup>

- 5y OS ~60-80%
- PPGL-attributable death 85% 
  - Modes of death?
- Poor prognostic factors: sporadic disease, hypersecretion
- Favorable prognostic factors: H&N disease, SDHx mutation (availability of drugs, usu younger, more often H&N locale, less likely to be hypersecretors)

</v-clicks>

<v-clicks>

## If benign<sup>2</sup>

- 5y OS \>95%

</v-clicks>


<Footnotes separator>
  <Footnote :number=1><a href="https://doi.org/10.1210/jc.2018-01968" rel="noreferrer" target="_blank">Hescot 2019</a></Footnote>
  <Footnote :number=2><a href="https://doi.org/10.3803%2FEnM.2020.35.1.157" rel="noreferrer" target="_blank">Al Subhi 2022</a></Footnote>
</Footnotes>

---

# Management

## Observation

- most of the time, surveil closely after initial resection (if it was done)

<br>

## Active

- next slide

---
layout: figure
figureFootnoteNumber: 1
figureUrl: ./nolting4.png
---

---
layout: index
indexEntries:
  - { title: "HemOnc.org entry", uri: "https://hemonc.org/wiki/Pheochromocytoma" }
  - { title: "ESMO-EURACAN Guidelines 2020", uri: "https://doi.org/10.1016/j.annonc.2020.08.2099" }
  - { title: "NANETS Guidelines 2021", uri: "https://doi.org/10.1097/mpa.0000000000001792" }
  - { title: "NCCN Guidelines", uri: "https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf" }
  - { title: "PathologyOutline Features to Report", uri: "https://www.pathologyoutlines.com/topic/adrenalparagangliomareport.html" }
indexRedirectType: external
---

# Resources

---

# Bibliography

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">
  <div class="csl-entry">Al Subhi, Abdul Rahman, Veronica Boyle, and Marianne S. Elston. “Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years.” <i>Journal of the Endocrine Society</i> 6, no. 9 (September 1, 2022): bvac105. <a href="https://doi.org/10.1210/jendso/bvac105">https://doi.org/10.1210/jendso/bvac105</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fjendso%2Fbvac105&amp;rft_id=info%3Apmid%2F35919261&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Systematic%20Review%3A%20Incidence%20of%20Pheochromocytoma%20and%20Paraganglioma%20Over%2070%20Years&amp;rft.jtitle=Journal%20of%20the%20Endocrine%20Society&amp;rft.stitle=J%20Endocr%20Soc&amp;rft.volume=6&amp;rft.issue=9&amp;rft.aufirst=Abdul%20Rahman&amp;rft.aulast=Al%20Subhi&amp;rft.au=Abdul%20Rahman%20Al%20Subhi&amp;rft.au=Veronica%20Boyle&amp;rft.au=Marianne%20S.%20Elston&amp;rft.date=2022-09-01&amp;rft.pages=bvac105&amp;rft.issn=2472-1972&amp;rft.language=eng"></span>
  <div class="csl-entry">De Filpo, G., G. Cantini, G. Rastrelli, G. Vannini, T. Ercolino, M. Luconi, M. Mannelli, M. Maggi, and L. Canu. “Management and Outcome of Metastatic Pheochromocytomas/Paragangliomas: A Monocentric Experience.” <i>Journal of Endocrinological Investigation</i> 45, no. 1 (January 1, 2022): 149–57. <a href="https://doi.org/10.1007/s40618-021-01629-x">https://doi.org/10.1007/s40618-021-01629-x</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1007%2Fs40618-021-01629-x&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Management%20and%20outcome%20of%20metastatic%20pheochromocytomas%2Fparagangliomas%3A%20a%20monocentric%20experience&amp;rft.jtitle=Journal%20of%20Endocrinological%20Investigation&amp;rft.stitle=J%20Endocrinol%20Invest&amp;rft.volume=45&amp;rft.issue=1&amp;rft.aufirst=G.&amp;rft.aulast=De%20Filpo&amp;rft.au=G.%20De%20Filpo&amp;rft.au=G.%20Cantini&amp;rft.au=G.%20Rastrelli&amp;rft.au=G.%20Vannini&amp;rft.au=T.%20Ercolino&amp;rft.au=M.%20Luconi&amp;rft.au=M.%20Mannelli&amp;rft.au=M.%20Maggi&amp;rft.au=L.%20Canu&amp;rft.date=2022-01-01&amp;rft.pages=149-157&amp;rft.spage=149&amp;rft.epage=157&amp;rft.issn=1720-8386&amp;rft.language=en"></span>
  <div class="csl-entry">Else, Tobias. “15 YEARS OF PARAGANGLIOMA: Pheochromocytoma, Paraganglioma and Genetic Syndromes: A Historical Perspective.” <i>Endocrine-Related Cancer</i> 22, no. 4 (August 1, 2015): T147–59. <a href="https://doi.org/10.1530/ERC-15-0221">https://doi.org/10.1530/ERC-15-0221</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1530%2FERC-15-0221&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=15%20YEARS%20OF%20PARAGANGLIOMA%3A%20Pheochromocytoma%2C%20paraganglioma%20and%20genetic%20syndromes%3A%20a%20historical%20perspective&amp;rft.jtitle=Endocrine-Related%20Cancer&amp;rft.volume=22&amp;rft.issue=4&amp;rft.aufirst=Tobias&amp;rft.aulast=Else&amp;rft.au=Tobias%20Else&amp;rft.date=2015-08-01&amp;rft.pages=T147-T159&amp;rft.spage=T147&amp;rft.epage=T159&amp;rft.issn=1351-0088%2C%201479-6821&amp;rft.language=en_US"></span>
  <div class="csl-entry">Fassnacht, M., G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H. R. Haak, R. de Krijger, F. Porpiglia, M. Terzolo, and A. Berruti. “Adrenocortical Carcinomas and Malignant Phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up†.” <i>Annals of Oncology</i> 31, no. 11 (November 1, 2020): 1476–90. <a href="https://doi.org/10.1016/j.annonc.2020.08.2099">https://doi.org/10.1016/j.annonc.2020.08.2099</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1016%2Fj.annonc.2020.08.2099&amp;rft_id=info%3Apmid%2F32861807&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Adrenocortical%20carcinomas%20and%20malignant%20phaeochromocytomas%3A%20ESMO%E2%80%93EURACAN%20Clinical%20Practice%20Guidelines%20for%20diagnosis%2C%20treatment%20and%20follow-up%E2%80%A0&amp;rft.jtitle=Annals%20of%20Oncology&amp;rft.stitle=Annals%20of%20Oncology&amp;rft.volume=31&amp;rft.issue=11&amp;rft.aufirst=M.&amp;rft.aulast=Fassnacht&amp;rft.au=M.%20Fassnacht&amp;rft.au=G.%20Assie&amp;rft.au=E.%20Baudin&amp;rft.au=G.%20Eisenhofer&amp;rft.au=C.%20de%20la%20Fouchardiere&amp;rft.au=H.%20R.%20Haak&amp;rft.au=R.%20de%20Krijger&amp;rft.au=F.%20Porpiglia&amp;rft.au=M.%20Terzolo&amp;rft.au=A.%20Berruti&amp;rft.date=2020-11-01&amp;rft.pages=1476-1490&amp;rft.spage=1476&amp;rft.epage=1490&amp;rft.issn=0923-7534%2C%201569-8041&amp;rft.language=English"></span>
  <div class="csl-entry">Fishbein, Lauren, Jaydira Del Rivero, Tobias Else, James R. Howe, Sylvia L. Asa, Debbie L. Cohen, Patricia L. M. Dahia, et al. “The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma.” <i>Pancreas</i> 50, no. 4 (April 2021): 469–93. <a href="https://doi.org/10.1097/MPA.0000000000001792">https://doi.org/10.1097/MPA.0000000000001792</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1097%2FMPA.0000000000001792&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20North%20American%20Neuroendocrine%20Tumor%20Society%20Consensus%20Guidelines%20for%20Surveillance%20and%20Management%20of%20Metastatic%20and%2For%20Unresectable%20Pheochromocytoma%20and%20Paraganglioma&amp;rft.jtitle=Pancreas&amp;rft.volume=50&amp;rft.issue=4&amp;rft.aufirst=Lauren&amp;rft.aulast=Fishbein&amp;rft.au=Lauren%20Fishbein&amp;rft.au=Jaydira%20Del%20Rivero&amp;rft.au=Tobias%20Else&amp;rft.au=James%20R.%20Howe&amp;rft.au=Sylvia%20L.%20Asa&amp;rft.au=Debbie%20L.%20Cohen&amp;rft.au=Patricia%20L.%20M.%20Dahia&amp;rft.au=Douglas%20L.%20Fraker&amp;rft.au=Karyn%20A.%20Goodman&amp;rft.au=Thomas%20A.%20Hope&amp;rft.au=Pamela%20L.%20Kunz&amp;rft.au=Kimberly%20Perez&amp;rft.au=Nancy%20D.%20Perrier&amp;rft.au=Daniel%20A.%20Pryma&amp;rft.au=Mabel%20Ryder&amp;rft.au=Aaron%20R.%20Sasson&amp;rft.au=Michael%20C.%20Soulen&amp;rft.au=Camilo%20Jimenez&amp;rft.date=2021-04&amp;rft.pages=469%E2%80%93493&amp;rft.spage=469&amp;rft.epage=493&amp;rft.issn=0885-3177&amp;rft.language=en-US"></span>
  <div class="csl-entry">Garcia-Carbonero, R., F. Matute Teresa, E. Mercader-Cidoncha, M. Mitjavila-Casanovas, M. Robledo, I. Tena, C. Alvarez-Escola, et al. “Multidisciplinary Practice Guidelines for the Diagnosis, Genetic Counseling and Treatment of Pheochromocytomas and Paragangliomas.” <i>Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico</i> 23, no. 10 (October 2021): 1995–2019. <a href="https://doi.org/10.1007/s12094-021-02622-9">https://doi.org/10.1007/s12094-021-02622-9</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1007%2Fs12094-021-02622-9&amp;rft_id=info%3Apmid%2F33959901&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Multidisciplinary%20practice%20guidelines%20for%20the%20diagnosis%2C%20genetic%20counseling%20and%20treatment%20of%20pheochromocytomas%20and%20paragangliomas&amp;rft.jtitle=Clinical%20%26%20Translational%20Oncology%3A%20Official%20Publication%20of%20the%20Federation%20of%20Spanish%20Oncology%20Societies%20and%20of%20the%20National%20Cancer%20Institute%20of%20Mexico&amp;rft.stitle=Clin%20Transl%20Oncol&amp;rft.volume=23&amp;rft.issue=10&amp;rft.aufirst=R.&amp;rft.aulast=Garcia-Carbonero&amp;rft.au=R.%20Garcia-Carbonero&amp;rft.au=F.%20Matute%20Teresa&amp;rft.au=E.%20Mercader-Cidoncha&amp;rft.au=M.%20Mitjavila-Casanovas&amp;rft.au=M.%20Robledo&amp;rft.au=I.%20Tena&amp;rft.au=C.%20Alvarez-Escola&amp;rft.au=M.%20Ar%C3%ADstegui&amp;rft.au=M.%20R.%20Bella-Cueto&amp;rft.au=C.%20Ferrer-Albiach&amp;rft.au=F.%20A.%20Hanzu&amp;rft.date=2021-10&amp;rft.pages=1995-2019&amp;rft.spage=1995&amp;rft.epage=2019&amp;rft.issn=1699-3055&amp;rft.language=eng"></span>
  <div class="csl-entry">Hamidi, Oksana. “Metastatic Pheochromocytoma and Paraganglioma: Recent Advances in Prognosis and Management.” <i>Current Opinion in Endocrinology, Diabetes &amp; Obesity</i> 26, no. 3 (June 2019): 146–54. <a href="https://doi.org/10.1097/MED.0000000000000476">https://doi.org/10.1097/MED.0000000000000476</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1097%2FMED.0000000000000476&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Metastatic%20pheochromocytoma%20and%20paraganglioma%3A%20recent%20advances%20in%20prognosis%20and%20management&amp;rft.jtitle=Current%20Opinion%20in%20Endocrinology%2C%20Diabetes%20%26%20Obesity&amp;rft.volume=26&amp;rft.issue=3&amp;rft.aufirst=Oksana&amp;rft.aulast=Hamidi&amp;rft.au=Oksana%20Hamidi&amp;rft.date=2019-06&amp;rft.pages=146-154&amp;rft.spage=146&amp;rft.epage=154&amp;rft.issn=1752-296X%2C%201752-2978&amp;rft.language=en"></span>
</div>

---

# Bibliography continued

<div class="csl-bib-body text-sm" style="line-height: 1.35; margin-left: 2em; text-indent:-2em;">
  <div class="csl-entry">Hescot, Segolene, Maria Curras-Freixes, Timo Deutschbein, Anouk van Berkel, Delphine Vezzosi, Laurence Amar, Christelle de la Fouchardière, et al. “Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study.” <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> 104, no. 6 (June 1, 2019): 2367–74. <a href="https://doi.org/10.1210/jc.2018-01968">https://doi.org/10.1210/jc.2018-01968</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fjc.2018-01968&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prognosis%20of%20Malignant%20Pheochromocytoma%20and%20Paraganglioma%20(MAPP-Prono%20Study)%3A%20A%20European%20Network%20for%20the%20Study%20of%20Adrenal%20Tumors%20Retrospective%20Study&amp;rft.jtitle=The%20Journal%20of%20Clinical%20Endocrinology%20%26%20Metabolism&amp;rft.stitle=The%20Journal%20of%20Clinical%20Endocrinology%20%26%20Metabolism&amp;rft.volume=104&amp;rft.issue=6&amp;rft.aufirst=Segolene&amp;rft.aulast=Hescot&amp;rft.au=Segolene%20Hescot&amp;rft.au=Maria%20Curras-Freixes&amp;rft.au=Timo%20Deutschbein&amp;rft.au=Anouk%20van%20Berkel&amp;rft.au=Delphine%20Vezzosi&amp;rft.au=Laurence%20Amar&amp;rft.au=Christelle%20de%20la%20Fouchardi%C3%A8re&amp;rft.au=Nuria%20Valdes&amp;rft.au=Fernando%20Riccardi&amp;rft.au=Christine%20Do%20Cao&amp;rft.au=Jerome%20Bertherat&amp;rft.au=Bernard%20Goichot&amp;rft.au=Felix%20Beuschlein&amp;rft.au=Delphine%20Drui&amp;rft.au=Letizia%20Canu&amp;rft.au=Patricia%20Niccoli&amp;rft.au=Sandrine%20Laboureau&amp;rft.au=Antoine%20Tabarin&amp;rft.au=Sophie%20Leboulleux&amp;rft.au=Bruna%20Calsina&amp;rft.au=Rossella%20Lib%C3%A9&amp;rft.au=Antongiulio%20Faggiano&amp;rft.au=Martin%20Schlumberger&amp;rft.au=Francoise%20Borson-Chazot&amp;rft.au=Massimo%20Mannelli&amp;rft.au=Anne-Paule%20Gimenez-Roqueplo&amp;rft.au=Philippe%20Caron&amp;rft.au=Henri%20J%20L%20M%20Timmers&amp;rft.au=Martin%20Fassnacht&amp;rft.au=Mercedes%20Robledo&amp;rft.au=Isabelle%20Borget&amp;rft.au=Eric%20Baudin&amp;rft.au=undefined&amp;rft.date=2019-06-01&amp;rft.pages=2367-2374&amp;rft.spage=2367&amp;rft.epage=2374&amp;rft.issn=0021-972X"></span>
  <div class="csl-entry">Kim, Jung Hee, Hyemi Moon, Junghyun Noh, Juneyoung Lee, and Sin Gon Kim. “Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service.” <i>Endocrinology and Metabolism (Seoul, Korea)</i> 35, no. 1 (March 2020): 157–64. <a href="https://doi.org/10.3803/EnM.2020.35.1.157">https://doi.org/10.3803/EnM.2020.35.1.157</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.3803%2FEnM.2020.35.1.157&amp;rft_id=info%3Apmid%2F32207276&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Epidemiology%20and%20Prognosis%20of%20Pheochromocytoma%2FParaganglioma%20in%20Korea%3A%20A%20Nationwide%20Study%20Based%20on%20the%20National%20Health%20Insurance%20Service&amp;rft.jtitle=Endocrinology%20and%20Metabolism%20(Seoul%2C%20Korea)&amp;rft.stitle=Endocrinol%20Metab%20(Seoul)&amp;rft.volume=35&amp;rft.issue=1&amp;rft.aufirst=Jung%20Hee&amp;rft.aulast=Kim&amp;rft.au=Jung%20Hee%20Kim&amp;rft.au=Hyemi%20Moon&amp;rft.au=Junghyun%20Noh&amp;rft.au=Juneyoung%20Lee&amp;rft.au=Sin%20Gon%20Kim&amp;rft.date=2020-03&amp;rft.pages=157-164&amp;rft.spage=157&amp;rft.epage=164&amp;rft.issn=2093-5978&amp;rft.language=eng"></span>
  <div class="csl-entry">Nölting, Svenja, Nicole Bechmann, David Taieb, Felix Beuschlein, Martin Fassnacht, Matthias Kroiss, Graeme Eisenhofer, Ashley Grossman, and Karel Pacak. “Personalized Management of Pheochromocytoma and Paraganglioma.” <i>Endocrine Reviews</i> 43, no. 2 (March 9, 2022): 199–239. <a href="https://doi.org/10.1210/endrev/bnab019">https://doi.org/10.1210/endrev/bnab019</a>.</div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_id=info%3Adoi%2F10.1210%2Fendrev%2Fbnab019&amp;rft_id=info%3Apmid%2F34147030&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Personalized%20Management%20of%20Pheochromocytoma%20and%20Paraganglioma&amp;rft.jtitle=Endocrine%20Reviews&amp;rft.stitle=Endocr%20Rev&amp;rft.volume=43&amp;rft.issue=2&amp;rft.aufirst=Svenja&amp;rft.aulast=N%C3%B6lting&amp;rft.au=Svenja%20N%C3%B6lting&amp;rft.au=Nicole%20Bechmann&amp;rft.au=David%20Taieb&amp;rft.au=Felix%20Beuschlein&amp;rft.au=Martin%20Fassnacht&amp;rft.au=Matthias%20Kroiss&amp;rft.au=Graeme%20Eisenhofer&amp;rft.au=Ashley%20Grossman&amp;rft.au=Karel%20Pacak&amp;rft.date=2022-03-09&amp;rft.pages=199-239&amp;rft.spage=199&amp;rft.epage=239&amp;rft.issn=1945-7189&amp;rft.language=eng"></span>
</div>
